More importantly, this interesting finding might raise potential clinical application in determining the therapeutic regimen for cholangiocarcinoma: (1) for Beclin 1 lowly expressed cholangiocarcinoma patients, especially for ICC patients that had a poor OS and PFS, aggressive postoperative adjuvant chemotherapy might be necessary, and would be of survival benefit; (2). The gene discussed is BECN1; the disease is cholangiocarcinoma.